Saturday 17 October 2026
Export NNOX’s income statement to Excel — free account
Nano-X Imaging Ltd.
NNOX Healthcare Medical Devices
Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.45
0.04
−8.16%
Follow NNOX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 6 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
13.93 | 37.44 | 36.76 | 43.42 | 0.00 | — | — | — | — |
Altman Z-Score |
(0.16) | 9.18 | 6.76 | 3.55 | 4.94 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(3.70) | 3.91 | 4.37 | 1.14 | 2.63 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/Operating CF |
(17.42) | (40.11) | (29.10) | (25.46) | (36.31) | — | — | — | — |
P/B ratio |
1.30 | 2.23 | 1.86 | 1.72 | 2.40 | — | — | — | — |
Price to Tangible BV |
2.28 | 3.55 | 3.17 | 3.16 | 5.31 | — | — | — | — |
EV/Sales |
10.66 | 32.89 | 29.13 | 34.86 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(3.40) | (10.14) | (6.44) | (6.89) | (16.19) | — | — | — | — |
EV/FCF |
(3.08) | (9.43) | (6.00) | (5.91) | (10.07) | — | — | — | — |
Quick Ratio |
3.03 | 4.26 | 5.41 | 3.13 | 1.70 | 47.65 | 0.40 | 0.00 | — |
Current Ratio |
3.96 | 5.63 | 5.71 | 3.29 | 1.80 | 49.06 | 0.48 | 0.21 | — |
Net Debt/EBITDA |
0.69 | 1.21 | 1.85 | 1.36 | 1.43 | 4.85 | 0.34 | 0.00 | — |
Debt/Assets |
1.93% | 1.46% | 1.60% | 1.66% | 1.09% | 0.61% | 4.43% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | (0.06) | 0.00 | — |
Asset Turnover |
0.07 | 0.05 | 0.04 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.54 | 0.68 | 0.74 | 0.38 | 0.62 | 0.49 | 0.24 | 1.92 | — |
Capex/Depreciation |
(0.36) | (0.24) | (0.17) | (0.11) | (11.16) | (67.00) | (2.36) | (2.09) | — |
| (45.62%) | (27.83%) | (29.49%) | (44.51%) | (23.64%) | (39.48%) | 297.63% | 25.18% | — | |
| (40.31%) | (24.97%) | (25.72%) | (36.70%) | (20.62%) | (35.33%) | (328.76%) | (205.82%) | — | |
ROIC |
(52.17%) | (26.37%) | (33.56%) | (51.35%) | (18.55%) | (146.64%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(94.27%) | (48.62%) | (52.64%) | (112.20%) | (77.69%) | (19.11%) | 216.97% | 29.90% | — |
Average Days of Receivables |
56.43 | 58.39 | 54.69 | 41.57 | 294.18 | — | — | — | — |
Research and Development Expense of Revenue |
147.73% | 178.87% | 262.99% | 309.01% | 1,313.04% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
209.29% | 229.24% | 287.13% | 531.94% | 3,201.07% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.37 | 0.33 | 0.37 | 0.39 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
32.18% | 64.35% | 69.04% | 217.10% | 1,442.18% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.24 | 0.14 | 0.18 | 0.12 | 0.03 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(41.17%) | (12.50%) | (16.56%) | (28.33%) | (8.73%) | — | — | — | — |
Free Cash Flow Yield |
(24.81%) | (9.32%) | (13.20%) | (13.57%) | (8.73%) | — | — | — | — |
Revenue per Share |
0.20 | 0.19 | 0.18 | 0.16 | 0.03 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.63) | (0.62) | (0.79) | (0.83) | (0.79) | (0.60) | (0.22) | (0.18) | — |
Capex per Share |
(0.06) | (0.05) | (0.06) | (0.14) | (0.48) | (0.39) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.69) | (0.67) | (0.85) | (0.97) | (1.27) | (0.99) | (0.22) | (0.18) | — |
Cash per Share |
0.76 | 0.98 | 1.46 | 1.49 | 1.84 | 5.99 | 0.32 | 0.00 | — |
Shareholders Equity per Share |
2.16 | 3.22 | 3.47 | 4.15 | 6.06 | 6.47 | (0.35) | (0.31) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.16 | 3.22 | 3.47 | 4.15 | 6.06 | 6.47 | (0.35) | (0.31) | — |
Free Cash Flow |
(45.00) | (39.36) | (48.08) | (50.56) | (61.22) | (35.42) | (5.65) | (3.74) | — |
Working Capital |
49.91 | 64.71 | 73.11 | 57.39 | 42.11 | 215.31 | (10.63) | (6.54) | — |
Capital Expenditures |
(4.21) | (2.77) | (3.30) | (7.17) | (23.16) | (13.94) | (0.12) | (0.07) | — |
Net Current Asset Value |
44.36 | 57.80 | 65.50 | 45.21 | 23.84 | 214.39 | (11.01) | (6.54) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.32 | 0.25 | 0.33 | 0.84 | 17.76 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.40 | 0.25 | 0.47 | 1.46 | 0.06 | 0.01 | 0.23 | 0.22 | — |
Cash ROIC |
(23.44%) | (15.75%) | (17.08%) | (16.94%) | (15.91%) | (7.95%) | 3,138.33% | 58.69% | — |
Accounts Receivable Turnover |
6.82 | 6.86 | 8.05 | 8.46 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
10.13 | 7.94 | 4.77 | 4.58 | 1.58 | 0.46 | 0.19 | 0.13 | — |
Inventory Turnover |
11.31 | 11.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
40.81 | 36.83 | 73.08 | 85.45 | 406.22 | 763.34 | 3,271.23 | 855.14 | — |
Days of Inventory on Hand |
43.42 | 24.89 | 52.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.91 | 1.64 | 1.23 | 1.01 | — | — | — | — | — |
Average Payables |
2.55 | 2.76 | 3.46 | 3.38 | 1.78 | 0.46 | 0.28 | 0.28 | — |
Average Inventory |
2.28 | 1.92 | — | — | — | — | — | — | — |
Average Assets |
186.08 | 214.33 | 236.29 | 308.55 | 299.66 | 124.01 | 6.86 | 0.93 | — |
Average Common Equity |
164.43 | 192.32 | 206.10 | 254.41 | 261.45 | 110.98 | (7.58) | (7.58) | — |
Columns are period end dates